PRESS RELEASE published on 05/22/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 Relief Therapeutics granted FDA Rare Pediatric Disease Designation for RLF-TD011 in treating epidermolysis bullosa, a rare genetic skin disorder. Potent antimicrobial & anti-inflammatory activity shown FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease Designation
BRIEF published on 05/15/2025 at 07:05, 1 year 2 months ago Relief Therapeutics Announces 2025 AGM Agenda Annual General Meeting Financial Statements Shareholder Voting Board Re-election Compensation Approval
BRIEF published on 05/15/2025 at 07:05, 1 year 2 months ago Relief Therapeutics annonce l'ordre du jour de l'assemblée générale annuelle 2025 États Financiers Assemblée Générale Annuelle Réélection Du Conseil D'administration Vote Des Actionnaires Approbation De L'indemnisation
PRESS RELEASE published on 05/15/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Publishes 2025 Annual General Meeting Agenda Relief Therapeutics announces agenda for its 2025 Annual General Meeting featuring key resolutions and re-elections. Meeting scheduled for June 12 in Geneva, Switzerland Shareholders Switzerland Relief Therapeutics Agenda 2025 Annual General Meeting
BRIEF published on 04/10/2025 at 07:05, 1 year 4 months ago Relief Therapeutics Announces 2024 Financial Results and Strategic Progress Biopharmaceutical Relief Therapeutics Rare Diseases 2024 Financial Results Pipeline Progress
BRIEF published on 04/10/2025 at 07:05, 1 year 4 months ago Relief Therapeutics annonce ses résultats financiers et ses progrès stratégiques pour 2024 Biopharmaceutique Maladies Rares THÉRAPEUTIQUE DE SECOURS Résultats Financiers 2024 Progrès Du Pipeline
PRESS RELEASE published on 04/10/2025 at 07:00, 1 year 4 months ago Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports 2024 financial results and provides a corporate update, emphasizing operational achievements, pipeline momentum, and strengthened financial position Biopharmaceutical Corporate Update Relief Therapeutics Rare Diseases 2024 Financial Results
BRIEF published on 03/06/2025 at 07:05, 1 year 5 months ago Relief Therapeutics Ends Merger Discussions with Renexxion Shareholder Value Relief Therapeutics Strategic Objectives Renexxion Merger Termination
BRIEF published on 03/06/2025 at 07:05, 1 year 5 months ago Relief Therapeutics met fin aux discussions de fusion avec Renexxion Valeur Actionnariale Objectifs Stratégiques THÉRAPEUTIQUE DE SECOURS Renexxion Fin De La Fusion
PRESS RELEASE published on 03/06/2025 at 07:00, 1 year 5 months ago Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion Relief Therapeutics terminates merger discussions with Renexxion after failing to meet key conditions. Company remains well-positioned with robust pipeline and cash reserves Relief Therapeutics Cash Reserves Therapeutic Pipeline Renexxion Merger Discussions
Published on 08/10/2026 at 15:30, 2 hours 28 minutes ago Silver Spruce Resources, Inc. Announces New Chief Financial Officer
Published on 08/10/2026 at 15:25, 2 hours 33 minutes ago Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
Published on 08/10/2026 at 14:30, 3 hours 28 minutes ago NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Published on 08/10/2026 at 13:30, 4 hours 28 minutes ago Sterling Expands High-Grade Copper Mineralization East at MEPS Intersecting 203 Metres at 0.51% CuEq: Includes 16.25 Metres at 2.31% CuEq and 9.50 Metres at 2.34% CuEq within 445 Metres at 0.40% CuEq
Published on 08/10/2026 at 13:00, 4 hours 58 minutes ago Alaska Energy Metals Announces Drilling Program for the Mcbride Prospect, Angliers-Belleterre Project, Quebec, Canada
Published on 08/10/2026 at 17:38, 20 minutes ago PATRIZIA delivers strong earnings growth with EUR 42.7m EBITDA (+46.6% y-o-y) in H1 2026
Published on 08/10/2026 at 17:11, 47 minutes ago CORRECTION FROM SOURCE: North Peak Commences 2026 Drilling Campaign at Prospect Mountain, Eureka, Nevada
Published on 08/10/2026 at 16:12, 1 hour 46 minutes ago dK Calls on PANDION AG Bondholders to Join Forces
Published on 08/10/2026 at 15:56, 2 hours 2 minutes ago Viromed Medical AG signs distribution partnerships for ViroCAP® in six additional markets
Published on 08/10/2026 at 15:46, 2 hours 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 08/10/2026 at 11:53, 6 hours 5 minutes ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:53, 6 hours 5 minutes ago GUILLEMOT CORPORATION |Informations relatives au nombre total de droits de vote et d’actions 31/07/2026
Published on 08/10/2026 at 11:36, 6 hours 22 minutes ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
